New facts on HLA genetics by Goulmy, E.A.J.M. et al.
Seminars in
HEMATÖLOGY
VOL XXI, NO 2, APRIL 1984
New Facts on HLA Genetics: Are They Relevant in Bone
Marrow Transplantation?
J. J. van Rood, B. de Jongh, F. H. J. Claas, E. Goulmy, J. W. Gratama, and M. J. Giphart
THE application of bone marrow transplanta-üon has been severely limited because for
almost two decades it was considered by most
teams to be succcssful only if the donor and
recipient were HLA identical siblings. This axi-
om, based upon animal experiments and the
early very poor results of bone marrow transplan-
tation in severe combined immune deficiency
between HLA non-identical donor recipient
pairs,17 is being slowly replaced by the realization
that HLA-incompatible grafts (from haploiden-
tical family members or unrelated (partially)
HLA-identical donors) can bc successful in a
considerable number of cases. Unfortunately, it
is impossible to predict which incompatible graft
will be safe for the patient and which will not be.
Such insight could come from two sources (1)
from improved knowledge of the structure and
function of the histocompatibility Systems in
general and the HLA System in particular, and
(2) from clinical experience. The first source will
be summarized in this chapter, the latter, the use
of HLA mismatched grafts and their clinical
outcome, is of too recent date, too heterogeneous,
and too limited to allow immunogenetic advice
to be formulated. The available clinical exper-
ience is reviewed in this issue76'84 and else-
where_2.,37,39,46,64
We will first review the products and genetics
of the HLA System emphasizing recent develop-
ments, its function, and its role in the recognition
of non-MHC deterrninants.
THE HLA SYSTEM: GENE PRODUCTS
The HLA System, the human major histocom-
patibility complex (MHC), designates a set of
linked genes on chromosome 6 that are highly
conseryed in evolution. The molecules encoded
by the HLA System can at present be divided into
three groups or classes on the basis of their
structure and function (Fig. l).7
Class I
Class I molecules are present as integral mem-
brane glycoproteins of nearly all nucleated cells,
and consist of a glycosylated heavy chain of
44,000 daltons101 binding noncovalently to ß2-
microglobulin (/32MG), a nonglycosylated light
chain of 12,000 daltons encoded on chromosome
15.38 The heavy chain can be divided into three
extracellular regions, called alpha-1, alpha-2,
and alpha-3, and two intracellular regions (Fig.
2).6' All three extracellular regions are folded
into domains, as is /32MG. ß2MG does not
penetrate the membrane, and the manner in
which ß2MG is associated with the domains of
the heavy chain of the molecule is not known.
The heavy chain genes are highly polymorphic
and are encoded by multiple alleles at the HLA-
A, HLA-B, and HLA-C loci (Table 1). The
/32MG subunit is probably nonpolymorphic.
By amino acid sequencing it has been shown
that the sequence homology between the heavy
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Fig. 1. The expanding HLA supergene.
chain of HLA-A2 and HLA-B7 is in the ränge of
80% to 85%.78 Comparing the HLA-A2 and
HLA-B7 sequences, amino acid differences
occur throughout the molecules. However, three
regions occur in which there is a clustering of
differences: one in alpha-1, (residue 65 to 80),
and two in alpha-2, (residues 105 to 115 and 174
to 178).78 Of interest is that the animo acid
sequence of the alpha-3 region is highly con-
served in these molecules. Moreover, the amino
«XI
(XI
oCZ
acid sequence of alpha-3 and /32MG is homolo-
gous to that of immunoglobulin (Ig) C region
domains, especially that of domain CH3 of
IgG.24 Among the functions of constant Ig
domains are activation of complement and bind-
ing to the Fc receptor. The alpha-3 region might,
by analogy, possess functional characteristics
related to those of Ig constant region domains. It
is in this context of Special interest that the
three-dimensional structure of the class I mole-
cules might resemble that of the immunoglobu-
lins.63 Furthermore, in the three-dimensional
structure of the immunoglobulins the antigen
binding site is located at a site similar to that of
the epitopes* or immunogenic determinants that
define the class I allelic specificities.60
The relevance of these data will be discussed in
the following section. In addition to the "classi-
cal" class I molecules, recent evidence suggests
that genes linked to HLA code for class I-like
molecules on the surface of human Τ lympho-
cytes.23'33109 Because of their limited tissue distri-
bution, these class I-like molecules are defined as
COOH
Closs I
Fig. 2. Arrangement of the class I and II antigen
domains, which may adopt a similar Overall structure.*1
*An epitope is a defined area on a molecule, which can
induce the formation of and interact with an alloimmune
antibody.
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Table 1. Complete Listing of Recognized HLA Specificities*
HLA-A
HLA-A1
HLA-A2
HLA-A3
HLA-A9
HLA-A 10
HLA-A 11
HLA-Aw19
HLA-Aw23(9)
HLA-Aw24(9)
HLA-A25(10)
HLA-A26(10)
HLA-A28
HLA-A29
HLA-Aw30
HLA-Aw31
HLA-Aw32
HLA-Aw33
HLA-Aw34
HLA-Aw36
HLA-Aw43
HLA-B
HLA-B5
HLA-B7
HLA-B8
HLA-B 12
HLA-B 13
HLA-B 14
HLA-B 15
HLA-Bw16
HLA-B 17
HLA-B 18
HLA-Bw21
HLA-Bw22
HLA-B27
HLA-Bw35
HLA-B37
HLA-Bw38(w16)
HLA-Bw39(w 16)
HLA-B40
HLA-Bw41
HLA-Bw42
HLA-Bw44(12)
HLA-Bw45(12)
HLA-Bw46
HLA-Bw47
HLA-Bw48
HLA-Bw49(w21)
HLA-Bw50(w21)
HLA-Bw51(5)
HLA-Bw52(5)
HLA-Bw53
HLA-Bw54(w22)
HLA-Bw55(w22)
HLA-Bw56(w22)
HLA-Bw57(17)
HLA-Bw58(17)
HLA-Bw59
HLA-Bw60(40)
HLA-Bw61(40)
HLA-Bw62(15)
HLA-Bw63(15)
HLA-Bw4
HLA-BW6
HLA-C
HLA-Cw1
HLA-Cw2
HLA-Cw3
HLA-Cw4
HLA-Cw5
HLA-Cw6
HLA-Cw7
HLA-Cw8
HLA-D
HLA-Dw1
HLA-Dw2
HLA-Dw3
HLA-Dw4
HLA-Dw5
HLA-Dw6
HLA-Dw7
HLA-Dw8
HLA-Dw9
HLA-Dw10
HLA-Dw11
HLA-Dw12
HLA-DR
HLA-DR1
HLA-DR2
HLA-DR3
HLA-DR4
HLA-DR5
HLA-DRw6
HLA-DR 7
HLA-DRw8
HLA-DRw9
HLA-DRw10
*The listing of broad specificities in parentheses after a narrow specificity, eg, HLA-Aw23(9) is optional.
"differentiation" molecules (with unknown func-
tion). They might be analogous to the murine Qa
and Tla molecules, which are referred to as class
IV molecules.32·96
Class II
Class II molecules are encoded by several loci
in the HLA-D/DR region. Using serological and
cellular techniques, class I molecules can be
detected (as membrane glycoproteins) on cells
with an immunological function such as Β lym-
phocytes, macrophages and activated Τ lympho-
cytes 110,114,122 (Table 1). Α class II molecule con-
sists of two polypeptide chains, both spanning the
cell membrane.54 The heavy, or alpha-chain of
32,000 to 36,000 daltons is tightly, but noncoval-
ently linked to the light or beta chain of 27,000 to
29,000 daltons. Peptide mapping studies indicate
that the light chain of a class II molecule is more
polymorphic than the heavy chain.55 The amino
acid sequences of those parts of the alpha and
beta chains that are adjacent to the cell mem-
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Table 2. Complotype Frequencies and Linkage
Disequilibria Among 623 Random Normal Chromosomes
from Caucasians
Cornptotype
SC31
SC01
FC31
SC30
SC42
SC61
FC30
FC01
SC02
SC21
SB42
SC33
SC22
SC32
Frequency
0.430
0.127
0.096
0.053
0.040
0.034
0.031
0.029
0.029
0.022
0.019
0014
0.013
0.011
Complotypes are given as abbreviated letters and numbers in
arbitrary Order- BF, C2, C4A, and C4B.126
brane show, as do the class I molecules, remark-
able and significant homology to the immuno-
globulin C region.58·123
Class III
Class III molecules are recognized as polymor-
phic plasma proteins that belong to the comple-
ment System and can be recognized by clectro-
phoresis.6 The structural genes for BF, C2, and
C4 (C4A and C4B) are localized in the HLA
System.2·48·6 Crossovers between the class III
genes have not been observed so that their
sequence order is unknown. Table 2 lists the most
common class III gene combinations, which are
also called complotypes.'25
GENETIC ORGANIZATION
The HLA System contains a set of tightly
linked genes that are usually inherited as one
group. Such a group of genes is called a haplo-
type. Each individual has a maternal and pater-
nal copy of chromosome six and, thus, a maternal
and paternal HLA haplotype and the Overall
chance that two siblings inherit the same haplo-
type is 25%. The HLA System from the HLA-A
to the HLA-DR locus spans on chromosome 6, a
region of around 1.8 centimorganf or recombina-
tion units,12' which is probably equivalent to
f The distance between two loci is measured by recombina-
tion frequency. One centimorgan equals one recombinant in
lOOmeioses.
about half a promille of the total human
genome.86 The genetic distance of 1.8 centimor-
gan between HLA-A and HLA-DR, may be an
underestimation. Recent studies suggest that
class I DNA sequences occur telomeric from the
HLA-A locus,33'77 and class II genes have been
detected centromeric of HLA-DR.92·52 Α sche-
matic representation of the genetic map of the
HLA System is shown in Fig. 1. From right
(telomeric) to left (centromeric), there is first a
group of loci that code for class I-like molecules
or Τ cell differentiation antigens.23·33'109 The sec-
ond group of loci codes for the "classical" HLA-
A, HLA-B, and HLA-C class I molecules.7 Fur-
ther to the left, four class III genes have been
identified, which code for the complement com-
ponents BF, C2, C4A, and C4B, respectively.
The order of the class III loci is not known, but
they are located between HLA-B and HLA-
DR.121 Centromeric of the class III genes is a set
of genes coding for class II molecules. By
employing serological and cellular techniques it
has been possible to define at least three segre-
gant series: DR, DC (LB-E, MB), and SB.90~
92,104,106,111 j - i
o w e v e r ) the definition of a segregant
series is complicated by the fact that the heavy
and light chain of a class II molecule is encoded
by an alpha gene and by a beta gene.53 There may
be more genes coding for the alpha and beta
chains of SB, DR, and DC, respectively. The
beta genes carry the allelic specificity and the
alpha genes do not, with the exception of the
alpha gene coding for DC. The estimated num-
ber of alpha and beta genes present varies from a
conservative one alpha for SB, one alpha for DR,
and two alpha for DC, to almost double these
figures. The number of beta genes is at least one
for SB, three for DR, and two for DC. The
Interpretation of the data should take into
account the DNA probes used and whether
hybridization conditions were stringent or not. If
the probes used can hybridize because of cross-
homology with the «3 exons of class I, the ß2MG
gene and the al and ß2 exons of the other class II
coding sequences, the estimate will be far too
high. This disregards the possibility of hybridiza-
tion with Ig heavy genes.
These separate gene products can form di-
mers, as has been shown in the mouse MHC
H-2-I region,72 both for genes on the same haplo-
type (ciscomplementation)53 and for genes on
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different haplotypes (transcomplementation).27
The principle of ciscomplementation and trans-
complementation is important for both our
genetic and functional understanding of the class
II gene products. It could imply, for instance,
that a class II molecule is expressed in the
offspring, which is encoded for by an alpha gene
of the father and a beta gene in the mother, and
thus is not expressed as such in either of the
parents.27'53·72
Returning to the genetic map, the characteri-
zation of the DR beta molecules indicates a
sequence homology with the mouse I-E prod-
ucts.3 The DC alpha chain shows homology with
the mouse I-A alpha chain.12 Table 3 summa-
rizes the number of class I and II loci that have
been recognized by DNA technology or protein
chemistry, cellular culture techniques, or serolo-
„
v
 4,7,11,14,26,28,58,59,62,66,77,104,117,118 T-L J y c e r v e S fQ
exemplify two points. First, protein chemistry
indicates that the number of different class I and
II molecules on the cell surface is twice as high as
detected by current routinely used serological
and cellular techniques. Second, the number of
molecules coded for at the DNA level might
again be at least twice as high as the number of
molecules at the cell membrane. We know next
to nothing about the transcription at the DNA
level under normal conditions, let alone in disease
or situations of intensive proliferation and differ-
entiation such as occur during bone marrow
repopulation.
POLYMORPHISM
We now come to one of the most striking
features of the MHC, which sets the MHC apart
from other genetic Systems, and which we have
mentioned earlier: its extreme balanced polymor-
phism.
Balanced polymorphism occurs when two or
more alleles are maintained in a population by
selection. The degree of polymorphism can be
expressed as the average heterozygosity for a
given locus.73 In humans, the average heterozy-
gosity for HLA-Α and HLA-B is above 90%.10
There is suggestive evidence that selection is a
driving force in maintaining the polymorphism of
the MHC. 1 0 Microbial agents are a likely candi-
date in this respect and De Vries et al25 have
shown that epidemics of typhoid and yellow fever
resulted in a shift from HLA gene frequencies
among survivors as compared to a nonaffected
control group.
Another genetic characteristic of the MHC is
the existence of linkage disequilibrium. When
two alleles of different loci are considered, then
the expected haplotype frequency can be calcu-
lated from the respective gene frequencies.10 If
the gene combinations occur at the predicted
frequencies, then these are said to be in equilibri-
um; any deviation from the equilibrium frequen-
cies is referred to as disequilibrium (parameter is
"delta") and defined by the equation: delta =
observed haplotype frequency minus expected
haplotype frequency. Linkage disequilibrium
can extend to more than two loci and a classical
example in the MHC is the greater-than-
expected occurrence of the haplotype HLA-
A l — B8-DR3. The MHC seems thus to fulfill
the criteria for a genetic System, according to Mi
and Morton:70 a unit of closely linked genetic
Information, whose phenotypic factors are non-
randomly associated in panmictic populations of
higher organisms.
The enormous polymorphism of the HLA sys-
tem has obviously important implications in bone
marrow transplantation. Because of its great
polymorphism, many parents will be heterozy-
gous at the class I and II loci, and segregation of
haplotypes in their offspring can be determined
unequivocally. This has led to the unfortunate
Table 3. HLA Class I and II Defined Loci and Molecules
Class I Class II
Detected by
DNA techiology
Protein chemistry
Cellular techniques
Serology
More than 30 heavy chain
genes77
8 heavy chains"7
3 allelic series I 4 B 9
3 allelic series7
A, B, C
4 ( - 6 ) α chain genes 4 6 2 " 8
8 (-15)0chain genes" 6 6
6-8 a-ß dimers58
3 allelic series28 10"
3 allelic series28
D/DR, DC, SB
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Situation in which some centers rely solely on the
phenotypic HLA identity of donor and recipient
to select a donor without checking whether geno-
typic identity is present as well. If one of the
parents is homozygous for the class I and II
antigens that are routinely typed for, such an
assumption can be erroneous (Fig. 3). One is
faced with this dilemma in about 10% of trans-
plants. Phenotypic identity should always be
confirmed by family segregation studies even if
the MLC test between donor and recipient is
negative.
In the unrelated donor-recipient Situation two
other points should be taken into account as well.
The first is that in humans, as well as in the
mouse, variants or mutants exist that cannot be
detected by serology but only by cellular tech-
niques or protein chemistry analysis.9'16·41·42·49·67·117
For instance, about 10% of individuals who are A2
seropositive carry one out of four different A2
variants that can only be recognized by cellular
techniques. Such variants have also been
described for B2716 and B35,41 but a systematic
analysis of all the class I antigens is lacking. The
equivalence of these variants in the mouse can
lead to strong homograft sensitivity and graft
versus host reactions.56'69 The second is the exis-
Fa
a: A2,B7,DR2
b : A2.B7.DR2
a - b?
c: AI ,B8,DR3
d: A9,B12,DR4
A2,B7,DR2
Ai,B8,DR3
a or b/c
A2,B7,DR2
A9.B12.DR4
a or b/d
A2,B7,DR2
AI,B8,DR3
a or b/c
Fig. 3. Example of a family where one parent is homo-
zygous for the class I and II (HLA-Α,Β and DR) antigens.
Child 1 and 3 seem identical for HLA. Genetic identity
cannot be proven on the basis of this HLA serotyping. Using
cytotoxic lymphocytes, which recognized subgroups of A2,
it could be shown that the a haplotype carried the most
common A2 group A2.1 and the haplotype b the A2.3
variant (van der Poel et al.). Child 1 and 3 are thus not class I
identical.
tence of splits or subgroups of the different HLA
alleles such as HLA-Aw23 and HLA-Aw24 of
HLA-A9. These are probably misnomers
because they reflect the existence of two separate
epitopes on the Η LA-Α molecule: one reactive
with anti-A9 and one with anti-A23 antibodies.
Table 4 summarizes the splits of the HLA-B
alleles and their relation to the supertypic HLA-
Bw4 and HLA-Bw6 antigens. Α HLA-Bw22
positive cell might, therefore, carry not only that
determinant but also the Bw6 and the e.g. Bw55
determinants. It was thought that the inventory
of these splits of the class I antigens was rather
complete but recent experience with monoclonal
antibodies indicates that there might exist far
more than described to date.
For the class II antigens the Situation is dif-
ferent. An indication of the existence of variants
recognized by DNA technology has been
described only recently and the mapping of the
splits has just been started. 8 0 1 0 2 Class II
restricted Τ cell lines might also be an ideal test
System with which to identify such variants.
The above serves to illustrate that the poly-
Table 4. HLA-B Locus Antigens and Their Inclusions in
Bw4 and Bw689
Bw4
B5
Bw53
Bw51
Bw52
Bw6
Bw35
B18
Bw44
Bw49
B12
Bw21
Bw45
Bw50
Bw63
B17
B37
(15A)
Bw57
Bw58
(17
(17
.1)
.2)
B15Bw62 (15b)
Bw46
Bw38 Bw16 Bw39
B13
Bw47
B27
Bw59 (B82)
B40 Bw60
Bw61
Bw48
Bw41
B7
B42
Bw22 Bw55
Bw56
Bw54
B8
B14
(40.1)
(40.2)
(22.1)
(22.2)
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morphism of the HLA System is much greater
than suggested by the presently officially identi-
fied alleles.' This will further complicate the
identification of unrelated class I and II identical
donors for a given patient. However, the impor-
tance of the different variants and splits for
activation of the homograft or graft versus host
reaction has not been systematically inventoried.
Some of them might be neutral and others might
actually activate suppressor cells47·100·124 and thus
diminish the reactivity.116
Summarizing this first section, we can con-
clude that the complexity of the HLA System is
even greater than the nomenclature of the offi-
cially recognized loci and alleles indicates, and
that each HLA molecule carries an unknown
number of different epitopes. Their function and
importance in the induction of GVHD remains to
be established.
One final point should be made. It has been
shown that the enormous polymorphism of the
MHC has a function in protecting a species from
extinction by a given virus or microbial agent.25
Although some individuals in a species will be
susceptible to the infectious agent and die, others
will survive because the MHC alleles they carry
allowed them to develop an adequate immune
response. It has also been shown that genetic
factors coded for by HLA predispose for certain
diseases mainly but not exclusively of immuno-
pathological origin. The polymorphism of HLA
can thus be used to identify individuals who are
at risk for certain diseases or complications. It is
really amazing that this powerful tool has not
been more frequently applied for a study of the
occurrence of GVH, interstitial pneumonia, or
leukemic relapse. In the previous issue a first
analysis was given of the occurrence of GVHD in
bone marrow grafted aplastic anemia patients;
HLA-B18 appears to increase the risk, and B8
and B35 seem to protect from it.98·09 Because the
data were only significant before correction for
the number of antigens tested, confirmation of
these findings is eagerly awaited. The authors
justly point out that the association might not be
primarily with the HLA-B locus but with the
class II loci. if on further analysis. the results
reinforce the importance of the HLA-B locus
antigens, then this might suggest that a viral
agent plays an important role in (some) cases of
GVHD. If a class II determinant is the deter-
mining factor an Ir gene effect seems more
likely.
THE ANTIGEN BINDING PROPERTIES
OF HLA MOLECULES
The Unding that parts of the class I and II
molecules are similar to that of the immuno-
globulins, the at least partial similarity of the
three dimensional structure and location of the
antigen binding sites on immunoglobulins and
epitopes, which determine the specificity on
HLA molecules, indicate that the HLA mole-
cules might have evolved from the same primor-
dial gene as the immunoglobulins. By implica-
tion, they might have similar functions. Earlier
studies failed to substantiate this18·68 but recent-
ly, positive evidence has been found showing that
HLA molecules themselves, or as part of a
receptor, have binding properties, and that they
might have a transmembrane transport function.
So far, the data almost exclusively relate to class
I molecules.
Α study performed by Peterson's group is
especially convincing. They showed that adenovi-
rus-infected rat fibroblasts express on their sur-
Fig. 4. Lymphocytes, sensitized with "Bl-anti HLA-A2
at room temperature wäre cultured at 37°C for various
periods.
Figs. 4 through 7 show subsequent stages of the loealiza-
tion of the immune complexes during culture as visuaiized
with electron microscopical autoradiography. In this photo-
graph a lymphocyte is shown prior to culturmg. The label is
found associated with the plasma membrane. Bar repre-
sents Ο 5 μ
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Fig. 5. This photograph was taken after 30 minutes of
culture. The label is found in loops at the cell surface. Bar
represents 0.5 μ. (See also legend to Fig 4.)
face a complex of a viral protein94 and the heavy
chain of class I molecules. This complex can be
endocytosed, passes the multivesicular bodies,
and ends up in the lysosomes, where it is
degraded. In other words, the heavy chain of the
class I molecule functions as a transport mole-
cule. An identical sequence of events was
observed by Giphart when he studied the fate of
radiolabeled, highly purified anti-A2 antibodies
after their interaction with HLA-A2 on mononu-
clear cells (Figs 4 through 7) u To be relevant,
the assumption must be made that the polymor-
phic epitopes that interact with the antibody can
in fact also interact with antigen."3 We will refer
to this point later.
Although in many instances such precise bio-
chemical and electron microscopic studies have
not been performed, there is agreement that
HLA antigens are involved in the presentaüon of
foreign, eg, viral, antigens to the immune sys-
tem.8 The combination of MHC and antigen
Ν
m
Fig. 6. This photograph was taken after three hours of
culture The label is found associated with so-called multi-
vesicular bodies (ν) Ν = nucleus Bar represents 0.5 μ. (See
also legend to Fig. 4.)
Fig. 7 The process of internahzation ends in the lyso-
somes, which can be recognized as a cluster of dense
bodies, which are associated with the label.34 Ga - Golgi
apparatus, Ν = nucleus, db =. dense body, m = mitochon-
drium. Bar represents 0.5 μ. (See also legend to Fig. 4.)
activates Τ helper cells, which in turn initiate the
cellular and humoral immune responses, which
destroy the infected cells. The point that may be
of importance in bone marrow transplantation is
that the same activated Τ killer cells do not only
recognize virus-infected autologous cells, but
also allogeneic uninfected cells. In other words,
the complex of self-MHC plus a foreign antigen,
eg, virus, resembles an allo-MHC antigen. This
is often referred to as altered seif. It could be an
important mechanism in the pathogenesis of
GVHD and also of GVHD-like disease after
transplantation.22'71 If the patient's cells are "al-
tered" through a viral infection, drugs, or irra-
diation, such cells might resemble alloantigens
and activate the donor lymphocytes. Because
during repopulation of the bone marrow the
subtle balance of Τ helper and suppressor cells is
easily disturbed, the ensuing activation may not
be self-limited
That this is not only conjecture is borne out by
the findings by Claas19 (see also Brand et al15) that
polymorphic determinants on platelets and neutro-
phils can interact with a large number of com-
monly used drugs (for instance cotrimoxazole,
salazopynne, dyta-urese, aldaclon, and carbenicil-
lin). These interaction products are recognized as
foreign and the cells carrying the complex of
polymorphic determinants and drugs are de-
stroyed by antibodies directed against this com-
plex. So far this has only been studied for poly-
morphic non-HLA antigens but it is likely that it
can also happen for HLA.
Α model study exemplifies this (Table 5).
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Table 5. Affinity of Penicillin for Allotypic Determinante
on Class I Antigens as Compared to That of HLA
Antibodies19
A.
B.
C.
(1)
(2)
(1)
(1)
(2)
Control
Sequence of Incubation
Penicillin + cells (15 min)
HLA antibodies
Penicillin, HLA antibodies + cells
simult.
HLA antibodies + cells (15 min)
Penicillin
. HLA antibodies h cells (30 min)
without pemcillin
Percentage of
Lymphocytes Dead
HLA Antibodies
α-Α2 α-Β 5
100 10
100 10
100 80
100 100
Penicillin was able to block the interaction of
anti-B5 antibody with the HLA-B5 antigen but
not of anti-A2 antibody with HLA-A2. In other
words, penicillin can interact and, through steric
hindrance, block the polymorphic epitope on the
B5 molecules but not on the A2 molecule.20 The
specificity of the blocking correlates with the
binding affinity of the HLA molecules with a
foreign molecule, in this case penicillin.
That such interaction products might alter the
cellular immune response is suggested by studies
on the effect of penicillin on the outcome of the
cell-mediated lympholysis (CML) test (Fig. 8).
The presence or absence of penicillin in the
induetion or effector phase of the CML test, or
during the preparation of the target cells,
influences to a large extent the outcome of the
test.51 Also, in this System an influence of the
presence or absence of class I variants can be
demonstrated.50
The common denominator of the above is the
finding that certain viral molecules or drugs can
alter the expression of self-MHC molecules and
thereby initiate an immune response that can
lead to GVHD.1 0 6 This might explain some of the
cases of GVHD not only in HLA-identical sib-
ling combinations but also in monozygotic and
autologous bone marrow transplants. Further-
more, as shown in animal modeis, Irradiation
alone can induce GVHD-like syndromes as
well.22'71 The finding that gut decontamination
can lead to diminished GVHD is in aecord with
such an assumption. The mechanism by which
bacteria could lead to GVHD is unclear.108 Per-
haps a process similar to that which has been
described in the pathogenesis of ankylosing spon-
dylitis is responsible. Geczy and his associates
have published studies that suggest that plasmids
in certain Klebsiella, Shigella, and Coli strains
can, after gut infection, modify the expression of
HLA-B27 leading again to a State of altered
seif.75 Their findings must still be confirmed.
Evidence that HLA molecules can act as
ligands, ie, molecules that can bind other struc-
Fig. 8. CTLs were gener ated in the presence
or absence of penicillin (100 lU/mL). After six
days of coculture, CTLs were collected and
washed three times with antibiotic-free RPMI
1640. Target cells were also eultured both in the
presence and in the absence of penicillin and
washed three times with antibiotic-free RPMI
1640. The CML assay was performed both with
and without penicillin. The presence or absence
of penicillin in the different phases of the assay is
indicated as + and —, respectively.
* LU30 is the number of effector cells χ 10 '
necessary to obtain 30% speeifie lysis of 1O4
target cells. These values were estimated by
linear regression analysis.49
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tures, is thus increasing.29'102 This is probably not
only the case in immunology but also in other
physiological processes such as endocrinology.
Evidence from four different groups indicates
that class I molecules form an integral part of the
insulin74 (Chvatchko et al, unpublished data),
epidermal growth factor88 and gamma-endor-
phin receptor (Claas et al, unpublished data). In
the first three studies monomorphic monoclonal
antibodies were used, in the latter, alloimmune
sera. This made it possible to determine whether
the different alleles of the class I molecules
influenced the effectiveness of the gamma-
endorphin receptor. Surprisingly, there existed a
significant correlation between the ability of
alpha-endorphin to block the interaction of class
I antibodies and their corresponding antigens
and the response in vivo of gamma endorphin
treatment on schizophrenia. To what extent such
findings are of relevance in bone marrow trans-
plantation (receptor for interleukins) or hemato-
logy (receptor for poietines) remains to be ascer-
tained.
In concluding, we would like to propose the
following working hypothesis. HLA molecules
can interact with a variety of foreign or self-
molecules, either per se or as part of a hormone
receptor. The interaction product of HLA and
foreign molecules can be endocytosed and
degraded. When the number of complexes on the
membrane exceeds the capacity of this process,
the complexes will remain on the surface and
activate Τ helper cells.
Not only microbial agents but also polymor-
phic non-HLA histocompatibility determinants
can be recognized in this way. Their recognition
and role in GVHD will be discussed in the last
section.
MHC-RESTRICTED NON-HLA ANTIGENS
It is of course logical to assume that differ-
ences of non-HLA-determinants between donor
and reeipient on their own alone or in conjunetion
with the factors described in the previous para-
graph can lead to GVHD. Systematic studies in
the mouse have documented this.45·57 However,
studies in humans have, with a few exceptions,
been negative.
Using the CML test, Goulmy has systemati-
cally investigated to what extent hyperimmu-
nized patients had MHC-restricted killer cells.
In patients suffering from aplastic anemia, she44
found cytotoxic lymphocytes (CTLs), which
were MHC restricted and directed against the
male minor histocompatibility antigen H-Y. The
first case concerned a woman who suffered from
aplastic anemia and had reeeived a large number
of blood and platelet transfusions. It was found
that her lymphocytes were able to kill the lym-
phocytes of her HLA identical brother. The cells
of this woman killed all A2 positive male cells
and (virtually) none of the female A2 positive
cells.
This was a typical example of an anti-H-Y/A2
restricted cytotoxic lymphocyte and since then
several other examples have been found.30'40'82'95
These CTLs react with class I antigens and H-Y,
and for this reason reactivity will not always
segregate with HLA. Of course, if families in
which all the children are males are studied, the
reactivity of such CTLs will segregate with the
HLA haplotypes.
Although these findings have been confirmed,
it is uncertain to what extent they are really of
clinical importance. Originally, it was reported
that female bone marrow donors lead more often
to complications than male donors13'36'97 but more
recent analyses do not confirm this.99 Further-
more, in such patients a correlation with the
presence of MHC-restricted H-Y CTLs has not
been found although this might be due to inade-
quate testing circumstances. The clinical impor-
tance of these HLA-A2 restricted anti-HY
CTLs thus remains open. This might be different
for a newly detected non-MHC determinant. Α
male patient (designated HA) was transplanted
because of an acute myeloid leukemia. He
reeeived a bone marrow transplant from an
HLA-identical sister. Their HLA type was A2,
B27, Bw62, Cwl, Cw3, DR1, DR4; MLC and
CML pretransplantation.were negative; and füll
chimaerism was induced. The clinical course was
complicated by grade III acute GVHD followed
by severe chronic GVHD. This patient was stud-
ied by using his posttransplantation cells as re-
sponder cells.43'44
Table 6 shows that posttransplant effector
cells of the patient were able to lyse the pretrans-
plantation cells. Posttransplantation patient cells
and cells of the bone marrow donor were not
lysed. It was concluded that the bone marrow
donor cells (after being primed in vivo) identified
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Table 6. Percentage Lysis Obtained With Posttransplant
Effector Cells of Patient HA43
Target Cells % Lysis
Patient HA (pretransplant)
Patient HA (posttransplant)
Bone marrow donor
Unrelated individual Α
Unrelated individual Β
Unrelated individual C
Unrelated individual D
+ 59
- 1
- 3
r-5
-7
+ 26
+ 35
something on the patient's cells, which was
absent from donor cells.
Next, the family of the patient was studied
(Fig. 9). The cells of both parents were killed by
the CTLs of the patient taken posttransplanta-
tion. The patient was positive before transplanta-
tion, the donor was negative, and of the Ihree
siblings haploidentical to the patient, the cells of
two were killed and of one were not. Thus, in this
one family, two examples in which HLA-identi-
cal siblings reacted differently with the CTL
cells recognizing the HA determinant were
encountered. To test the specificity of the CTL, a
panel of over 100 people was typed (Table 7).
There was a clear correlation with A2, 90% of
the A2-positive cells were killed. However, vari-
ants of A2 as defined by CTL typing49·"2 were
not killed. The A2-positive cells, which were not
HLA-A2 variants and were not killed, were
obtained from the bone marrow donor, the
haploidentical sister, and three unrelated indi-
viduals. Since then other examples have been
found as well. Additionally, the lymphocytes of
the patient also contained CTLs, which reacted
with a part of the B27- and Bw62-positive cells.
The Situation appears to be very similar to that
of HY with a number of important differences.
First, this minor HA antigen might have a very
high frequency, at least in A2-positive individu-
als. Whether this minor antigen is localized on
the sixth chromosome is not known. Second, it is
also unknown wheiher the clones, which are
restricted to B27 and Bw62, are directed against
the same HA antigen as the A2-restricted clone.
ab
CML : +91%
02
cd
CML· : +84%
04 03
patient donor
ad ad ac ac ac
+82% -3% +85% +92% +6%
Fig. 9. The percentage of lysis in family HA.
Following this observation, a systematic study
was performed in part in collaboration with the
bone marrow transplant team in the hospital
Saint Louis (Paris, France)."5 The data col-
lected to date indicate that especially chronic
GVHD correlates with the presence of incompat-
ibility between the donor and recipient for the
minor antigen HA. Using a prolonged sensitiza-
tion phase, MHC-restricted CTLs can be
detected posttransplantation in about half of the
patients with GVHD. They are directed against
HA and other non-HA determinants. So far they
seem not to be identical to or to be associated
with the known blood group Systems, comple-
ment markers or intracellular enzymes.
The study of these MHC-restricted non-HLA
markers is likely to have important consequences
for our understanding and prevention of GVHD.
How they can contribute to our understanding is
self-evident. As far as prevention is concerned,
the following applies. If the logistics of the use of
unrelated donors have been resolved, such donors
might in some cases be preferred above an HLA-
identical sibling donor, if the sibling donor is
mismatched for a minor histocompatibility anti-
gen such as HA and the unrelated donor is not."6
As long as partial HLA class I and II identity
between donor and host exists it does not seem
likely that m^-T-B cell interaction would become
Table 7. Analysis of HLA Restricted Arrti-Minor HA Antigen Lysis*
HLA Serotyping of Target Cells
CML
HLA-A2 +
Bw27 - B62 -
3 8
5
B27 +
A2 - Bw62 -
2
5
Bw62 +
A2 - B27 -
7
3
Othe
0
4 4
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so hampered as to severely inhibit immunological
reconstitution. Perhaps a more serious problem
might be the increased chance of leukemic
relapse in patients without GVHD.120
CONCLUSIONS
If we summarize what has been discussed in
the three previous sections and assess its impor-
tance in bone marrow transplantation, the fol-
lowing picture emerges.
The class I (and, in all probability, the class II
molecules) carry not one immunogenic deter-
minant or epitope, but perhaps as many as sev-
eral dozen. Furthermore, the number of class I
and II loci that code for molecules that are
expressed and, thus, present on the cell mem-
brane, is at least twice as high as the number now
routinely typed for, ie, the HLA-A, HLA-B,
HLA-C, HLA-DR, and HLA-DC or HLA-MB
loci. Because some of these loci are located
outside the region between HLA-A and HLA-
DR, unidentified crossovers can occur. As a
result, some presumed HLA-identical siblings
will in fact not be identical for these loci. This has
been documented for the SB locus, which is not
routinely typed for.93·105 Because HLA-identical
siblings are identified by serotyping, class I vari-
ants that can thus far be detected only by cell-
mediated lympholysis cannot be detected either.
This will be especially relevant if a class I antigen
occurs as a homozygote (by serotyping) in one of
the parents (Fig. 3). This can be another reason
that apparently HLA-identical siblings are in
fact not identical.
Another complication can arise through the
fact that a class II antigen, eg, HLA-DR is coded
for by one of at least four alpha and five beta
genes, which can also combine in transposition.
This means that alpha genes of the father can
combine with beta genes of the mother and, thus,
give rise to an antigen that is absent in either
parent. Because it is known that during prolifera-
tion and differentiation the expression of the only
two class II molecules on which such Information
is available can differ,31 one could speculate that
during the repopulation of the bone marrow,
donor and recipient, although they are geneti-
cally HLA identical, differ in their phenotypic
expression of the class II molecules. Thus, cross-
overs of unidentified class I or II loci, the pres-
ence of a class I variant in one of the parents and
differential expression of class II determinants
could be the reason that apparently HLA-identi-
cal siblings are in fact different. The techniques
to identify these differences have only recently
become available. How important they are as a
cause for GVHD remains to be assessed.
HLA molecules show amino acid sequence
homology with immunoglobulins and this has
lead to a quest to identify possible immunoglobu-
lin-like functions of the HLA molecule. These
have indeed been found. HLA molecules can
interact with a variety of drugs, hormones, and
viral proteins. They might be important as trans-
membrane transport molecules. In bone marrow
transplantation it is of Special interest that the
interaction product of a given class I molecule
and a viral protein can resemble another allelic
class I molecule.83 This might cause GVHD both
in HLA-identical sibling donor-recipient pairs as
well as in autologous or monozygotic bone mar-
row transplants, which are known to be triggered
by viral infections.35'85
Non-HLA determinants, which are HLA
restricted and thus far only detectable by the
cell-mediated lympholysis test can cause GVHD
as well. They seem especially relevant in chronic
GVHD.
Thus, a better understanding of the genetics of
HLA (crossover of unidentified loci, variants,
and differential expression of loci), its function,
(the complex of a class I antigen and a viral
protein resembles an alloantigen), and its impor-
tance in the recognition of non-HLA determi-
nants are all relevant in bone marrow transplan-
tation.
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